Ranolazine 500 mg (DrugBank: Ranolazine)
6 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 1 |
58 | 肥大型心筋症 | 2 |
86 | 肺動脈性肺高血圧症 | 0 |
96 | クローン病 | 0 |
113 | 筋ジストロフィー | 0 |
114 | 非ジストロフィー性ミオトニー症候群 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03472950 (ClinicalTrials.gov) | June 11, 2018 | 1/3/2018 | Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis | Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis | ALS | Drug: Ranolazine 500 MG;Drug: Ranolazine 1000 MG | University of Kansas Medical Center | Gilead Sciences | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2011-004507-20-DE (EUCTR) | 02/07/2012 | 17/10/2011 | SHCM | RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY) - RESTYLE- HCM STUDY | symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 17.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Ranexa Product Code: Ranolazine 500 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 750 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 1000 mg PR tablets INN or Proposed INN: RANOLAZINE | Menarini International Operations Luxembourg S.A. | NULL | Not Recruiting | Female: yes Male: yes | 100 | Spain;Germany;Italy | |||
2 | EUCTR2011-004507-20-ES (EUCTR) | 19/01/2012 | 13/10/2011 | SHMC | RANOLAZINE IN PATIENTS WITH SYMPTOMATICHYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDYASSESSING THE EFFECTS ON EXERCISE CAPACITY,DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS | symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 14.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Ranexa Product Code: Ranolazine 500 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 750 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 1000 mg PR tablets INN or Proposed INN: RANOLAZINE | Menarini International Operations Luxembourg S.A. | NULL | Not Recruiting | Female: yes Male: yes | 100 | Spain;Germany;Italy |